Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

4Total
P 1 (1)
P 2 (2)
P 3 (1)

Trial Status

Completed4

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 4 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT02019069Phase 2Completed

CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT00006363Phase 3Completed

Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

NCT00027872Phase 2Completed

Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

NCT00101296Phase 1Completed

Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Showing all 4 trials

Research Network

Activity Timeline